Quantcast

Latest DelMar Pharmaceuticals Inc. Stories

2014-05-20 20:22:05

VANCOUVER, British Columbia and MENLO PARK, Calif., May 20, 2014 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar" and "DelMar Pharma") provided a quarterly update and a summary of progress toward the Company's goals for the year. DelMar also announced an investor conference call to take place on Thursday June 5, 2014 at 11:30 am EDT. Details and log-in information will be posted on the website at www.delmarpharma.com in advance of the call. Highlights from the...

2014-05-16 08:26:16

30mg/m2 dose cohort had been completed; enrollment of 40mg/m2 cohort has been initiated VANCOUVER, British Columbia and MENLO PARK, Calif., May 16, 2014 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar") is pleased to provide an update on the company's ongoing Phase I/II clinical trial for VAL-083 in recurrent glioblastoma multiforme (GBM). DelMar has completed enrollment of VAL-083 dose Cohort 6 and advanced to Cohort 7. DelMar most recently presented...

2014-05-14 20:23:34

VANCOUVER, British Columbia and MENLO PARK, Calif., May 14, 2014 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar") today announced that the Company will present an abstract entitled, "Phase I/II study of dianhydrogalactitol (VAL-083) in patients with recurrent malignant glioblastoma multiforme (GBM)," at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO), which is being held May 30th to June 3rd at the McCormick Place Convention Center in...

2014-05-01 08:36:12

Glioblastoma is the most common form of primary brain cancer VANCOUVER, Canada and MENLO PARK, Calif., May 1, 2014 /PRNewswire/ -- Jeffrey Bacha, president and CEO of DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar Pharma" or "DelMar") discusses new clinical research and treatments in development for glioblastoma, the most common and severe form of brain cancer. Less than one out of three patients will survive two years after their diagnosis. DelMar is a cancer-focused company developing...

2014-04-09 12:31:10

VAL-083 therapy is well tolerated to date; dose limiting toxicity has not been reached after fifth cohort (20mg/m2) VANCOUVER, British Columbia and MENLO PARK, Calif., April 9, 2014 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar") today announced an update on its ongoing Phase I/II clinical trial with VAL-083 in the treatment of refractory glioblastoma multiforme (GBM). The company's new data are being presented in a poster entitled, "A Phase I/II Study of VAL-083 in...

2014-04-07 12:33:26

New data demonstrates VAL-083 is superior to standard platinum-based chemotherapy in an established in vivo model of non-small cell lung cancer (NSCLC) VANCOUVER, British Columbia, MENLO PARK, Calif. and SAN DIEGO, April 7, 2014 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar") today announced the presentation of new data in a poster entitled, "In vivo efficacy of VAL-083 in the treatment of non-small cell lung cancer." DelMar's data was presented on Sunday, April 6, 2014...

2014-04-02 12:32:51

New data demonstrates VAL-083 has promise as a potential treatment of non-small cell lung cancer (NSCLC) and glioblastoma multiforme (GBM) VANCOUVER, British Columbia and MENLO PARK, Calif., April 2, 2014 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar") today announced that the Company would present two abstracts at the 105th Annual Meeting of the American Association for Cancer Research (AACR), which is being held April 5-9, 2014, in San Diego. The Company...

2014-03-20 08:29:42

VANCOUVER, British Columbia and MENLO PARK, Calif., March 20, 2014 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar" and "DelMar Pharma") provided an update as of the quarter ended December 31, 2013 and a summary of progress toward the Company's goals for the year. DelMar also announced an investor conference call to take place today at 1 pm EDT. Details and log-in information will be posted on the website at www.delmarpharma.com in advance of the call....

2014-03-06 08:29:14

NEW YORK, March 6, 2014 /PRNewswire/ -- SeeThruEquity, a leading New York City based independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has issued an update note on DelMar Pharmaceuticals, Inc. (OTCQB: DMPI), a biotechnology company focused on proven cancer therapies in new orphan drug indications where patients are failing modern targeted or biologic treatments. The note is focuses on DelMar Pharmaceuticals...

2014-03-04 08:31:55

VANCOUVER, British Columbia and MENLO PARK, Calif., March 4, 2014 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar" and "DelMar Pharma") a pharmaceutical company developing its VAL-083 chemotherapy as a potential new therapy for glioblastoma multiforme, today announced that Jeffrey A. Bacha, President and CEO of DelMar Pharmaceuticals, Inc., will present at the upcoming 26(th) Annual ROTH Capital Conference. Mr. Bacha will make a corporate presentation to...


Word of the Day
omadhaun
  • A fool; a simpleton: a term of abuse common in Ireland and to a less extent in the Gaelic-speaking parts of Scotland.
This word is partly Irish in origin.